Related Experiment Video
Updated: Apr 30, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells
María de Guadalupe Chávez-López1, Elizabeth Hernández-Gallegos, Alma Y Vázquez-Sánchez
1*Department of Pharmacology, and †Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del I.P.N., Avenida Instituto Politécnico Nacional 2508, Mexico City, México.
Objective:
Cervical cancer is a major cause of mortality among women in developing countries. Thus, it is necessary to offer novel therapies to treat this malignancy. Astemizole has been suggested as a novel and interesting anticancer agent because it targets several proteins involved in cancer including Eag1 (ether à-go-go-1) potassium channels. Eag1 has been proposed as a tumor marker for different types of cancer. Actually, we previously suggested Eag1 channels as cervical cancer and dysplasia markers. Besides, Eag1 has been proposed as a therapeutic target for different malignancies. However, the effect of astemizole in cervical cancer cells is unknown. Therefore, we investigated the effect of astemizole on the proliferation and apoptosis of cervical cancer cells.
Methods:
Five cervical cancer cell lines (HeLa, SiHa, CaSki, INBL, and C-33A) were cultured according to manufacturer's instructions. Eag1 protein expression was studied by immunocytochemistry. Cell proliferation was assayed with the MTT method, and apoptosis was investigated by flow cytometry.
Results:
Eag1 protein expression was observed in different cell lines. Astemizole decreased cell proliferation in up to 40% and increased apoptosis severalfold in all the cell lines studied.
Conclusions:
Our results suggest astemizole as a potential therapy for cervical cancer.
Insights
Astemizole significantly reduced cervical cancer cell proliferation and increased apoptosis, suggesting its potential as a novel therapy for this malignancy. Eag1 (ether à-go-go-1) channels are implicated in cancer progression.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cervical cancer poses a significant mortality risk, particularly in developing nations.
- Novel therapeutic strategies are crucial for managing this malignancy.
- Astemizole exhibits anticancer properties by targeting proteins like Eag1 (ether à-go-go-1) potassium channels, which are implicated in various cancers.
Purpose of the Study:
- To investigate the effects of astemizole on cervical cancer cell proliferation and apoptosis.
- To explore the potential of astemizole as a therapeutic agent for cervical cancer.
Main Methods:
- Utilized five human cervical cancer cell lines (HeLa, SiHa, CaSki, INBL, C-33A).
- Assessed Eag1 protein expression via immunocytochemistry.
- Quantified cell proliferation using the MTT assay and apoptosis via flow cytometry.
Main Results:
- Eag1 protein expression was confirmed across the studied cervical cancer cell lines.
- Astemizole treatment led to a reduction in cell proliferation by up to 40%.
- Astemizole significantly increased apoptosis in all tested cell lines.
Conclusions:
- Astemizole demonstrates potent anti-proliferative and pro-apoptotic effects on cervical cancer cells.
- These findings support astemizole as a promising candidate for novel cervical cancer therapies.
More Related Videos
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
02:34Inhibition of Cdk Activity
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle